• STereotactic Body Radiotherapy (SBRT) for Oligoprogressive Breast Cancer

  NCT06489821

  Not yet recruitingInterventionalNot ApplicableUpdated Jul 8, 2024
• Stereotactic Radiotherapy Versus Palliative Conventional Radiotherapy for Oligoprogressive Metastatic Cancers

  NCT06918951

  RecruitingInterventionalNot ApplicableUpdated Dec 15, 2025
• Stereotactic Ablative Radiotherapy for Oligo-Progressive Disease REfractory to Systemic Therapy in Metastatic Cancer

  NCT04989725

  RecruitingInterventionalPhase 2Updated Jul 22, 2026
• The Role of Stereo-tActic BoDy RadIotherApy iN Oligo-Progressive MalignanT Disease

  NCT04122469

  Active, not recruitingInterventionalNot ApplicableUpdated Jun 4, 2026
• Stereotactic Body Radiotherapy or Standard of Care for Prostate Oligoprogressive Cancer

  NCT06927635

  RecruitingInterventionalPhase 2Updated Jul 7, 2026
• Stereotactic Body Radiotherapy for Oligo-Progression Metastatic Non-Small Cell Lung Cancer

  NCT06523673

  RecruitingInterventionalPhase 3Updated Aug 30, 2024

ClinicalTrials.gov ID

NCT06925984

Lead Sponsor

Jules Bordet InstituteOTHER

Overall Status

Recruiting

Study Type

Interventional

Phase

Not Applicable

Enrollment

48Estimated

Last Update Posted

Feb 2, 2026Actual

Start Date

Oct 30, 2025Actual

Primary Completion Date

May 1, 2028Estimated

Completion Date

May 1, 2030Estimated

Official Title

The Oligopro-Breast Study: Stereotactic Radiotherapy for Oligoprogressive ER+/HER- Metastatic Breast Cancer, a Prospective Phase 2 Study

Brief Summary

The Oligopro-Breast trial is a Phase II study targeting women with ER+/HER2- metastatic breast cancer who have been on endocrine therapy and/or CDK4/6 inhibitors for at least 6 months, and show progressive disease at 1-3 extracranial metastases, which are treatable locally. The trial aims to investigate if treating these resistant metastases with SBRT (or other local treatments if SBRT is not possible) can extend the use of the current systemic therapy.

Patients will continue their existing systemic treatment while receiving SBRT on all progressive lesions. If new oligoprogression occurs, SBRT will be performed again. A new systemic treatment line will start if there is polyprogression (more than 3 lesions at once), progression of more than 6 lesions over 12 months, intracranial progression, or lesions that cannot be treated locally.

The scientific question is whether local treatment of resistant metastases can prolong the effectiveness of ongoing systemic therapy, which is particularly beneficial if the treatment is well-tolerated. The primary objective is to measure the proportion of patients surviving without changing their systemic treatment line at 6 months after SBRT.

This trial is significant for patients as it explores a method to potentially extend the duration of effective and well-tolerated treatments, offering hope for better management of metastatic breast cancer.

• OligoProgressive Metastatic Disease

• SBRT

Ages Eligible for Study

Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

Female

Accepts Healthy Volunteers

No

Eligibility Criteria

Inclusion Criteria:

• ECOG performance status 0-2.
• Histologically confirmed ER+/HER2- MBC.
• History of polymetastatic disease. Patients with genuine oligometastatic disease and 1-3 oligoprogressive lesions are only allowed if ablative therapy of all metastases is deemed impossible.
• Under 1st to 2nd systemic treatment line with hormonotherapy and/or CDK4/6 inhibitors for at least 6 months before progression.
• Progressive disease at 1-3 extracranial sites.
• Ability to treat all progressive lesions locally according to the treating radiation oncologist.

Exclusion Criteria:

• Second malignancy if it is not in complete remission.
• Previous local treatment for oligoprogression under the current systemic treatment line
• Current progression in a lesion that has been treated with SBRT before and is not amendable for surgery or radiofrequency ablation (RFA).
• Progressive or newly diagnosed brain metastases. Known brain metastases that have been nonprogressive for at least 6 months, are not an exclusion criterion.
• Inability to continue the same ST line after local therapy (for example because of toxicity or patient refusal).
• Pregnancy.
• Inability to sign the informed consent.

Primary Purpose

Treatment

Allocation

N/A

Interventional Model

Single Group Assignment

Masking

None (Open Label)

Lead Sponsor

Jules Bordet InstituteOTHER

+32 9 332 30 15

radiotherapie@azgroeninge.be+32 56 63 39 03